EditR: A Method to Quantify Base Editing from Sanger Sequencing

Mitchell G. Kluesner, Derek Nedveck, Walker S. Lahr, +4

The CRISPR Journal

TALEN-based Gene Correction for Epidermolysis Bullosa

Mark J. Osborn, Colby G. Starker, Amber McElroy, +14

Molecular Therapy

Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors

Beau R. Webber, Cara-lin Lonetree, Mitchell G. Kluesner, +12

Nature Communications

Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases

Mark J. Osborn, Beau R. Webber, Friederike Knipping, +19

Molecular Therapy

A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy

Emily J. Pomeroy, John Hunzeker, Mitchell G. Kluesner, +13

Molecular Therapy

Cancer ImmunosurveillanceImmunologyTherapeutic VaccineImmune Checkpoint InhibitorImmune Cell Therapy +6

Efficient targeted integration directed by short homology in zebrafish and mammalian cells

Wesley A. Wierson, Jordan M. Welker, Maira P. Almeida, +25

eLife

Engineering T cells to enhance 3D migration through structurally and mechanically complex tumor microenvironments

Erdem D. Tabdanov, Nelson J. Rodríguez-Merced, Alexander X. Cartagena‐Rivera, +10

Nature Communications

Fanconi Anemia Gene Editing by the CRISPR/Cas9 System

Mark J. Osborn, Richard Gabriel, Beau R. Webber, +11

Human Gene Therapy

BioinformaticsOff-target EffectCrispr/cas9 SystemEngineeringDesigner Nucleases +13

CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cells

Mitchell G. Kluesner, Walker S. Lahr, Cara-lin Lonetree, +12

Nature Communications

Rapid DNA replication origin licensing protects stem cell pluripotency

Jacob P. Matson, ‎Raluca Dumitru, Philip Coryell, +8

eLife

GeneticsCell PluripotencyOrigin LicensingCell CycleEpigenetics +14